Novavax (NVAX) Exchange Rate Effect (2013 - 2026)
Novavax (NVAX) posted quarterly Exchange Rate Effect of -$18000.0 for Q1 2026, up 98.06% year-over-year from -$9087.9 in Q1 2025, and up 98.95% quarter-over-quarter from -$1.7 million in Q4 2025.
Novavax (NVAX) Exchange Rate Effect (2013 - 2026) Analysis & Trends
Novavax's Exchange Rate Effect history runs 14 years deep, the most recent figure standing at -$18000.0 for Q1 2026.
- In Q1 2026, Exchange Rate Effect rose 98.06% year-over-year to -$18000.0; the TTM figure through Mar 2026 stood at $6.8 million (up 218.39% YoY), while the FY2025 annual figure was $5.9 million, up 175.96% from the prior year.
- Exchange Rate Effect for Q1 2026 stood at -$18000.0, up from -$1.7 million in the prior quarter.
- The five-year high for Exchange Rate Effect was $9.3 million in Q3 2023, with the low at -$10.7 million in Q4 2024.
- The 5-year median for Exchange Rate Effect is -$18000.0 (2026), against an average of $347000.0.
- The sharpest annual moves came in 2023 and 2025: Exchange Rate Effect slumped 738.11% in 2023, then jumped 5167.95% in 2025.
- Novavax's Exchange Rate Effect stood at $4.3 million in 2022, then slumped by 31.57% to $2.9 million in 2023, then sank by 467.4% to -$10.7 million in 2024, then soared by 84.05% to -$1.7 million in 2025, then soared by 98.95% to -$18000.0 in 2026.
- Business Quant data shows NVAX's Exchange Rate Effect at -$18000.0 in Q1 2026, -$1.7 million in Q4 2025, and $658000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.84 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -14,590.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -2.45 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -287,000.00 |
| 10 | Novavax | 1.33 Bn | 607.37 Mn | 42.45 Mn | -176,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -176,000.00 |
| Jun 30, 2026 | -176,000.00 |
| Mar 31, 2026 | -18,000.00 |
| Mar 31, 2026 | -18,000.00 |
| Dec 31, 2025 | -1.71 Mn |
| Dec 31, 2025 | -1.71 Mn |
| Sep 30, 2025 | 658,000.00 |
| Sep 30, 2025 | 658,000.00 |
| Jun 30, 2025 | 7.91 Mn |
| Jun 30, 2025 | 7.91 Mn |
| Mar 31, 2025 | -930,000.00 |
| Mar 31, 2025 | -930,000.00 |
| Dec 31, 2024 | -10.72 Mn |
| Dec 31, 2024 | -10.72 Mn |
| Sep 30, 2024 | 6.03 Mn |
| Sep 30, 2024 | 6.03 Mn |
| Jun 30, 2024 | -156,000.00 |
| Jun 30, 2024 | -156,000.00 |
| Mar 31, 2024 | -2.96 Mn |
| Mar 31, 2024 | -2.96 Mn |